Geron Corp (NASDAQ:GERN)

CAPS Rating: 3 out of 5

A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS.

Results 1 - 20 of 162 : 1 2 3 4 5 6 7 8 9 Next »

Recs

0
Member Avatar TerryHoodSr (79.84) Submitted: 4/21/2015 11:47:47 AM : Outperform Start Price: $3.94 GERN Score: -2.55

BP 4 TP 5.5 (Oppenheimer)

Recs

0
Member Avatar TMusta (57.28) Submitted: 3/22/2015 4:23:03 PM : Outperform Start Price: $3.95 GERN Score: -2.97

Imetelstat could be blockbuster drug and a new stadard on cancer treatment.

Recs

0
Member Avatar Haugurafpeningum (28.29) Submitted: 3/5/2015 5:28:57 AM : Outperform Start Price: $2.90 GERN Score: +32.51

Stock Doctor

Recs

0
Member Avatar Nickpar (66.49) Submitted: 1/21/2015 12:53:05 AM : Outperform Start Price: $3.37 GERN Score: +9.39

Lot going on in hot here favor!!!

Recs

0
Member Avatar stockexpert2b (< 20) Submitted: 12/7/2014 10:14:51 PM : Outperform Start Price: $3.75 GERN Score: +0.83

cure for cancer is worth?

Recs

0
Member Avatar oncqueen (71.29) Submitted: 4/3/2014 11:57:03 AM : Outperform Start Price: $2.02 GERN Score: +78.75

This is a very promising drug that is delayed, not dead, and is trading at left-for-dead prices. I'm going to buy some in the real world, too.

Recs

0
Member Avatar fwstash (< 20) Submitted: 1/24/2014 12:50:31 PM : Outperform Start Price: $5.67 GERN Score: -49.43

So what I see is that after having a failed drug and trimming the company's output was smart money. Focusing on a drug that has been treating and working towards a true cure, total remission, get's me excited. As this year progressives Geron will succeed only to the amount the CEO allows, possible a sellout but hopeful for a merge.

Recs

0
Member Avatar LexSC (54.67) Submitted: 12/6/2013 4:34:49 PM : Outperform Start Price: $5.90 GERN Score: -51.33

This a gamble on my part. If the drug they are developing pans out, they can name their price. If not this is a cheap strike out.

Recs

0
Member Avatar cavemantrader (83.99) Submitted: 11/7/2013 11:18:51 AM : Outperform Start Price: $6.75 GERN Score: -62.47

GERN is unique developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Company also has zero debt which is a plus. This will surprise to the upside in a big way.

Recs

2
Member Avatar fatmoneyrz (99.31) Submitted: 10/16/2013 10:29:14 PM : Outperform Start Price: $4.05 GERN Score: -27.78

I've got a mysterious vibe about GERN. When I was walking the city streets very early this morning a fortune teller on a small side street drew me in and wanted to read my palms. While doing so I looked into her crystal ball and saw big $$$, pleasure yachts and Lear jets, and also the letters GERN. The fortune teller stated great wealth was in my future, and stated fundamentals and valuation didn't matter-- that I would buy something that would shoot up to an astronomical degree-- much like a company called ACAD, and I would know it when I saw it. When the market opened this morning I bought GERN.

Recs

2
Member Avatar zzlangerhans (99.80) Submitted: 8/16/2013 12:07:37 AM : Underperform Start Price: $1.52 GERN Score: -128.66

Geron spiked up a little on rather vague descriptions of progress made in the IST of imetelstat for myelofibrosis but I maintain this one surviving indication for one surviving pipeline candidate doesn't merit an enterprise value of more than 100M.

Recs

0
Member Avatar rknapton (< 20) Submitted: 8/6/2013 7:35:50 PM : Underperform Start Price: $1.34 GERN Score: -162.83

Short. Essentially no revenues. Burning through cash rapidly

Recs

0
Member Avatar LouisAIrl (< 20) Submitted: 9/10/2012 11:55:00 AM : Outperform Start Price: $1.25 GERN Score: +160.69

Down too much today

Recs

0
Member Avatar KimLanners (< 20) Submitted: 11/15/2011 7:18:24 PM : Underperform Start Price: $1.68 GERN Score: -60.00

down

Recs

0
Member Avatar Terbius (< 20) Submitted: 9/3/2011 2:39:47 PM : Outperform Start Price: $2.60 GERN Score: -36.76

stem cell research is the most promising new medical technology

Recs

0
Member Avatar StockDoc (< 20) Submitted: 8/27/2011 2:52:54 PM : Outperform Start Price: $2.58 GERN Score: -27.60

Phase 2 study results pending and multi[le applications with core research should push to new highs

Recs

0
Member Avatar GTcollegekid (36.30) Submitted: 7/9/2011 10:21:24 AM : Outperform Start Price: $4.35 GERN Score: -70.87

stem cell

Recs

0
Member Avatar bddc4 (< 20) Submitted: 5/12/2011 12:14:28 PM : Outperform Start Price: $4.97 GERN Score: -80.09

stem cells are the future in medicine.

Recs

0
Member Avatar Kenergy (62.81) Submitted: 5/11/2011 4:25:22 AM : Outperform Start Price: $6.11 GERN Score: -111.07

Give this 12 - 18 months and it will be $50/share. The down side or the depressing side is that it will trade between $5.25 and $4.70 until the day it takes off. 12% chance it fails.

Recs

0
Member Avatar segundo100 (< 20) Submitted: 3/19/2011 9:24:59 PM : Outperform Start Price: $4.87 GERN Score: -84.54

Their current biomedical research has great potential, the next uptrend pike should not be far from now.

Featured Broker Partners


Advertisement